Use of weight loss medications in patients after bariatric surgery.
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose of review Weight regain after bariatric surgery is unfortunately a common occurrence. In this article, we have reviewed the data addressing this clinical problem focusing on pharmacological management of weight regain.Recent findings Data from several small, non-randomized, retrospective, and prospective studies provide evidence that a number of pharmacological options, both FDA approved and off-label, are effective in mitigating and managing weight regain after bariatric surgery. There is a suggestion that the optimal time to initiate weight loss medications may be at the time of weight plateau, rather than after weight regain. Adjuvant pharmacotherapy can help treat weight regain after bariatric surgery. Future studies should investigate the optimal timing for starting weight loss medications, as well as the best medication or combinations of medicines, for managing postoperative weight regain in different patient groups, including those who have undergone different types of bariatric surgeries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, rapid weight regain after bariatric surgery may signal a need for additional intervention, such as antiobesity medications.9,126”
From Obesity Management in Adults: A Review (2023) · cites this paper as [126]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Self-citationO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Courcoulas, A. P., King, W. C., Belle, S. H., Berk, P., Flum, D. R., Garcia, L., Gourash, W., Horlick, M., Mitchell, J. E., Pomp, A., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2017.5025 · Cited by 699
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621
Weight Recidivism Post-Bariatric Surgery: A Systematic Review
Karmali, S., Brar, B., Shi, X., Sharma, A. M., de Gara, C., & Birch, D. W. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1070-4 · Cited by 574
Bohdjalian, A., Langer, F. B., Shakeri-Leidenmühler, S., Gfrerer, L., Ludvik, B., Zacherl, J., & Prager, G. (2010) · Obesity Surgery · doi:10.1007/s11695-009-0066-6 · Cited by 503
Grazing and Loss of Control Related to Eating: Two High‐risk Factors Following Bariatric Surgery
Colles, S. L., Dixon, J. B., & O'Brien, P. E. (2008) · Obesity · doi:10.1038/oby.2007.101 · Cited by 420
King, W. C., Hinerman, A. S., Belle, S. H., Wahed, A. S., & Courcoulas, A. P. (2018) · JAMA · doi:10.1001/jama.2018.14433 · Cited by 414
Trends in weight regain following roux-en-Y gastric bypass (RYGB) bariatric surgery
Cooper, T. C., Simmons, E. B., Webb, K., Burns, J. L., & Kushner, R. F. (2015) · Obesity Surgery · doi:10.1007/s11695-014-1560-z · Cited by 305
Binge Eating Among Gastric Bypass Patients at Long-term Follow-up
Kalarchian, M. A., Marcus, M. D., Wilson, G. T., Labouvie, E. W., Brolin, R. E., & LaMarca, L. B. (2002) · Obesity Surgery · doi:10.1381/096089202762552494 · Cited by 300
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Self-citationStanford, F. C., Alfaris, N., Gomez, G., Ricks, E. T., Shukla, A. P., Corey, K. E., Pratt, J. S., Pomp, A., Rubino, F., & Aronne, L. J. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.10.018 · Cited by 206
Self-citationWeight regain after Roux-en-Y: A significant 20% complication related to PYY
Meguid, M. M., Glade, M. J., & Middleton, F. A. (2008) · Nutrition · doi:10.1016/j.nut.2008.06.027 · Cited by 153
Wharton, S., Kuk, J. L., Luszczynski, M., Kamran, E., & Christensen, R. A. G. (2019) · Clinical Obesity · doi:10.1111/cob.12323 · Cited by 144 · cited 1×
“…(S) patients S=15 Post-surgical patients with inadequate weight loss or weight regain 5.3±3.3 years Average 4.2 (3–7) months Kg weight loss 7.5±4.3 Wharton et al. (2019) Liraglutide 3 mg/day in surgical patients RYGB=53 AGB=50 SG=14 Post-surgical patients with weight regain 7.8±5.7 years…”
BackgroundInfluentialBody Weight Changes with β-Blocker Use: Results from GEMINI
Messerli, F. H., Bell, D. S. H., Fonseca, V. A., Katholi, R. E., McGill, J. B., Phillips, R. A., Raskin, P., Wright, J. T., Bangalore, S., Holdbrook, F. K., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.10.017 · Cited by 134
Weight regain after bariatric surgery—how should it be defined?
Nedelcu, M., Khwaja, H. A., & Rogula, T. G. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.04.028 · Cited by 121
Definition determines weight regain outcomes after sleeve gastrectomy
Lauti, M., Lemanu, D. P., Zeng, I. S. L., Su’a, B., Hill, A. G., & MacCormick, A. D. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.02.029 · Cited by 120
Tratamento de curto prazo com liraglutide no reganho de peso após cirurgia bariátrica
Pajecki, D., Halpern, A., Cercato, C., Mancini, M., Cleva, R. D., & Santo, M. A. (2013) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/s0100-69912013000300005 · Cited by 93
Efficacy of adjuvant weight loss medication after bariatric surgery
Nor Hanipah, Z., Nasr, E. C., Bucak, E., Schauer, P. R., Aminian, A., Brethauer, S. A., & Cetin, D. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.10.002 · Cited by 93 · cited 1×
“…patients with inadequate weight loss or weight regain RYGB=62.6 (SD=39.1) months SG=20.1 (SD=5.2) months 12 months % total weight loss RYGB=8.1 SG=3.3 (p=.0515) Hanipah et al. (2018) Phentermine 37.5 mg/day (P), phentermine/topiramate 7.5/46–15/92 mg/day (PT), lorcaserin 10 mg BID (Lor),…”
BackgroundInfluentialSuliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86
Schwartz, J., Suzo, A., Wehr, A. M., Foreman, K. S., Mikami, D. J., Needleman, B. J., & Noria, S. F. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1979-x · Cited by 84
Gorgojo-Martínez, J. J., Feo-Ortega, G., & Serrano-Moreno, C. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.013 · Cited by 60 · cited 1×
“…comorbidities P=median 35.3 months PT=median 36.3 months 3 months % excess weight loss P=12.8 (95% CI 4.25, 8.44) PT=12.9 (95% CI 1.08, 6.54) Gorgojo-Martinez et al. (2016) Liraglutide 1.2–1.8 mg/day in nonsurgical (NS) and surgical (S) NS=149 S=15 Patients with diabetes prescribed…”
BackgroundInfluentialZilberstein, B., Pajecki, D., de Brito, A. C. G., Gallafrio, S. T., Eshkenazy, R., & Andrade, C. G. (2004) · Obesity Surgery · doi:10.1381/0960892041590926 · Cited by 58
Toth, A. T., Gomez, G., Shukla, A. P., Pratt, J. S., Cena, H., Biino, G., Aronne, L. J., & Stanford, F. C. (2018) · Children · doi:10.3390/children5090116 · Cited by 57
Self-citationMetformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Self-citationSrivastava, G., & Buffington, C. K. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3141-z · Cited by 51
Current concepts in management of weight regain following bariatric surgery
Shukla, A. P., He, D., Saunders, K. H., Andrew, C., & Aronne, L. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1447922 · Cited by 49
Self-citationArd, J. D., Beavers, D. P., Hale, E., Miller, G., McNatt, S., & Fernandez, A. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.04.017 · Cited by 41
Zoss, I., Piec, G., & Horber, F. F. (2002) · Obesity Surgery · doi:10.1381/096089202321144685 · Cited by 34
Stanford, F. C., Toth, A. T., Shukla, A. P., Pratt, J. S., Cena, H., Biino, G., & Aronne, L. J. (2018) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2018.0037 · Cited by 30
Self-citationStanford, F. C. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.10.020 · Cited by 22
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Mok, J., Adeleke, M. O., Brown, A., Magee, C. G., Firman, C., Makahamadze, C., Jassil, F. C., Marvasti, P., Carnemolla, A., Devalia, K., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.2930 · Cited by 178
“Injection site reaction 3 (9) 2 (6) 5 (7)”
Jensen, A. B., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06484-8 · Cited by 161
“considered semaglutide a reasonable therapeutic option for weight regain after bariatric surgery [23], and the first data on the efficacy of semaglutide in this patient population was recently reported in a retrospective observational study from Germany, in patients with insufficient weight loss or weight regain after…”
BackgroundAnti-obesity carbonic anhydrase inhibitors: challenges and opportunities
Supuran, C. T. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2121393 · Cited by 76
Metadata
- Authors
- Redmond, I. P., Shukla, A. P., & Aronne, L. J.
- Affiliations
- Weill Cornell Medicine (US)
- Corresponding author
- Redmond, Ilana P.
- Venue
- Current Obesity Reports
- Published
- 2021-01-25
- Volume
- 10
- Issue
- 2
- Pages
- 81-89
- ISSN
- 2162-4968 (ISSN-L)
- OpenAlex
- W3125515680
- Cited by
- 50
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 14 · 2023: 15 · 2022: 7 · 2021: 2
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Body Contouring and Surgery
- Keywords
- anti-obesity drugs, pharmacotherapy, off-label drug use, adjuvant pharmacotherapy, bariatric surgery outcomes
- MeSH terms
- Liraglutide, Topiramate, Humans, Obesity, Phentermine, Postoperative Period, Weight Gain, Weight Loss, Anti-Obesity Agents, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.